Braveheart Bio opened higher at $20.97, compared with its previous close of $20.90. In the last trading session, the stock traded between $20.01 and $21.30. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Braveheart Bio is now worth
$ 113.91
Giving a profit of
$ 13.91 (13.91%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.40 (-1.89%)
Day High
$21.30
Day Low
$20.01
Day Open
$20.97
Prev Close
$20.90
Volume
2,15,351
1W Return
2.10%
1M Return
1.16%
3M Return
-19.48%
6M Return
13.91%
1Y Return
13.91%
Fundamentals
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-
EPS (TTM)
-
Investment Returns
1 Week
2.10%
1 Month
1.16%
3 Months
-19.48%
6 Months
13.91%
9 Months
13.91%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Mar 26
0.0
Jun 26
Updates
7Nov
Hengrui, Braveheart show sustained HCM drug efficacy at 52 weeks
HRS/BHB-1893 demonstrated sustained efficacy in oHCM with 79% of patients achieving Valsalva LVOT gradient below 30 mmHg at Week 52. Peak oxygen uptake improved by 2.7 mL/kg/min and KCCQ-CSS score rose by 17.3 points from baseline. 57% of patients remained on the 40 mg twice-daily starting dose, supporting a simplified dosing regimen. Preclinical and nHCM data suggest potential to address underlying pathophysiology with diastolic benefits. Braveheart Bio scheduled investor event for November 6, 2026, to discuss planned TRUEHEART-HCM study.
6 days ago
20Oct
Cantor Fitzgerald reiterates Overweight on Braveheart Bio, keeps $40 target
Cantor Fitzgerald reiterated Overweight rating on Braveheart Bio. Price target maintained at $40 per share. Analyst Olivia Brayer Saunders issued the rating.
